Amneal Pharmaceuticals’ $100 Million Acquisition of KSP

Holland & Knight LLP advised Kashiv Biosciences LLC on the deal.

Kashiv Biosciences LLC, a fully integrated specialty biopharmaceutical company, announced the $100 million sale of its subsidiary Kashiv Specialty Pharmaceuticals LLC (KSP) to Amneal Pharmaceuticals LLC, a wholly owned subsidiary of Amneal Pharmaceuticals, Inc. (NYSE:AMRX). 

KSP, headquartered in New Jersey, focuses on the development of complex generic pharmaceuticals, innovative drug delivery platforms and novel 505(b)(2) drugs.

Amneal, which is also based in New Jersey, is a fully-integrated pharmaceutical company focused on the development, manufacture and distribution of generic and specialty drug products. The company has manufacturing operations in North America, Asia and Europe.

Holland & Knight’s representation of Kashiv was led by Partners Amy Leder (Picture) and Charles Weiss. They were assisted by Partners John Dierking, Marc Druckman, Alan Schwartz and Victoria Zerjav, and Associates Anush Yegyazarian and Max Lubin.

Involved fees earner: John Dierking – Holland & Knight; Marc Druckman – Holland & Knight; Amy Leder – Holland & Knight; Max Lubin – Holland & Knight; Alan Schwartz – Holland & Knight; Charles Weiss – Holland & Knight; Anush Yegyazarian – Holland & Knight; Victoria Zerjav – Holland & Knight;

Law Firms: Holland & Knight;

Clients: Kashiv Biosciences LLC;

Print Friendly, PDF & Email
Martina Bellini

Author: Martina Bellini